CN100589807C - Compound and its processing technology for compound sulfamonomethoxine sodium injection - Google Patents
Compound and its processing technology for compound sulfamonomethoxine sodium injection Download PDFInfo
- Publication number
- CN100589807C CN100589807C CN200710034835A CN200710034835A CN100589807C CN 100589807 C CN100589807 C CN 100589807C CN 200710034835 A CN200710034835 A CN 200710034835A CN 200710034835 A CN200710034835 A CN 200710034835A CN 100589807 C CN100589807 C CN 100589807C
- Authority
- CN
- China
- Prior art keywords
- injection
- sodium
- amount
- sulfamonomethoxine sodium
- trimethoprim
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a formula of a daimeton sodium injection and making process thereof, and aims at providing a formula of compound recipe formulation compound recipe daimeton sodium injection capable of preventing and curing mixing infection contamination of a plurality of virus, bacilli, mycoplasma and bloodworm and making process thereof. Said formula and making process are characterized in that the formula is as follows: daimeton sodium of150g, trimethoprim of 30g, ofloxacin of 20g, dexamethasone sodium phosphate of 1g, propylene glycol of 600ml, ethanol amine of right amount, benzenemethanol of 40ml, ethylenediamine tetraacetic acid disodium of 100mg, anhydrous sodium sulfite of 2g, active carbon of 3g, and water for injection of added to 1000ml; the organic combinationof daimeton sodium, trimethoprim, ofloxacin, dexamethasone sodium phosphate together can effectively exhibits effects of medicament cooperation, synergism and long acting, and improves medicament curative effects, expands antibacterial spectrum, improves medicament side-effects, can achieve the objective of one injection for effect onset and 3-5 injection for healing; wrapping material is saved to reduce the cost of products.
Description
Technical field
The present invention relates to the biological medicine manufacturing industry, in particular, relate to the prescription and the processing technology of a kind of composite sulfamonomethoxine sodium injection of veterinary drug.
Background technology
In recent years, China by south to many pig farms in north and raise scattered family outburst a kind of with hyperpyrexia, infect fast, inappetence even useless exhausted, strange illness that mortality rate is high, some pig farm even therefore " be annihilated ", organize relevant expert's field diagnostic and analysis through the Ministry of Agriculture, be diagnosed as multiple virus and antibacterial, the Mycoplasma unknown high fever of pigs that (comprising mycoplasma pneumoniae, Eperythrozoon), toxoplasmatic mixed infection caused.Many experts begin this disease is worked as toxoplasmosis, eperythrozoonosis is prevented and treated, after merely prevent and treat again when reproductive and respiratory syndrome, influenza, swine fever, the result all ends in failure, blindly medication of raiser, and folk prescription medical treatment effect extreme difference, cause mortality rate high, once causing numerous raisers' fear, therefore research and develop the compound preparation of the mixed infection of a kind of energy multiple virus of control and antibacterial, mycoplasma, Tubifex, be not only the needs of animal husbandry development, also imperative.
Summary of the invention
The objective of the invention is to overcome the shortcoming of conventional art, the compound preparation composite sulfamonomethoxine sodium injection of the mixed infection of a kind of energy multiple virus of control and antibacterial, mycoplasma, Tubifex is provided.
In order to solve the technical problem of above-mentioned existence, the present invention is achieved by following technical proposals, it is characterized in that, the prescription of described composite sulfamonomethoxine sodium injection is:
Sulfamonomethoxine sodium 150g
Trimethoprim 30g
Ofloxacin 20g
Dexamethasone sodium phosphate 1g
Propylene glycol 600ml
Benzyl alcohol 40ml
Ethanolamine is an amount of
Disodiumedetate 100mg
Anhydrous sodium sulfite 2g
Active carbon 3g
Water for injection adds to 1000ml
The processing technology of described composite sulfamonomethoxine sodium injection is:
The first step, at first that sulfamonomethoxine sodium 150g, trimethoprim 30g, ofloxacin 20g, dexamethasone sodium phosphate 1g, propylene glycol 600ml, ethanolamine is an amount of, benzyl alcohol 40ml, disodiumedetate 100mg, anhydrous sodium sulfite 2g, active carbon 3g, water for injection add to 1000ml by relevant quality standard after the assay was approved again by purgation production;
Second goes on foot, gets the water for injection of amount of preparation 20%, in pill tank, be heated to 40～50 ℃, add disodiumedetate, anhydrous sodium sulfite stirring and dissolving successively, add the total amount ethanolamine of (4%) approximately again, the adding ofloxacin fully stirs and makes its dissolving after stirring evenly, and adds sulfamonomethoxine sodium again and stirs molten, standby;
The 3rd step, get the propylene glycol of amount of preparation, in pill tank, be heated to 70～80 ℃, add the trimethoprim of amount of preparation, stir molten, standby;
The 4th step, to get water for injection an amount of, in preparation tank, adds dexamethasone sodium phosphate and stir molten, standby;
The 5th step, with second step prepare reserve liquid under agitation add in the 3rd reserve liquid that make of step, add in the 4th reserve liquid that make of step again and stir, regulate pH value to 10.0～11.5 with ethanolamine, the benzyl alcohol that adds amount of preparation stirs evenly, add active carbon in 70～80 ℃ of absorption 15 minutes, add to the full amount of water for injection, stir evenly, coarse filtration, fine straining, promptly get the composite sulfamonomethoxine sodium injection, detect qualified after, packing;
The 6th step, again in 100 ℃ of flowing steam sterilizations 30 minutes, lamp inspection, seal bag, product inspection be qualified get final product the composite sulfamonomethoxine sodium injection.
Below the invention will be further described:
The main effective ingredient of composite sulfamonomethoxine sodium injection product, the chemical molecular of sulfamonomethoxine sodium, trimethoprim, ofloxacin, dexamethasone sodium phosphate, structural formula, dosage form, character, specification:
Chemical name: sulfamonomethoxine sodium, molecular formula: C
11H
11N
4NaO
3SH
2O molecular weight: 320.29
Structural formula:
Chemical name: trimethoprim, molecular formula: C
14H
18N
4O
3, molecular weight: 290.32,
Structural formula:
Chemical name: ofloxacin, molecular formula: C
18H
20FN
3O
4Molecular weight: 361.38,
Structural formula:
Chemical name: dexamethasone sodium phosphate, molecular formula: C
22H
28FNa
2O
8P, molecular weight: 516.41 structural formulas:
Dosage form: final sterilization small-volume injection.
Character:
(a) sulfamonomethoxine sodium is white crystals or crystalline powder; Odorless, bitter in the mouth.
(b) trimethoprim is white or off-white color crystalline powder; Odorless, bitter in the mouth.
(c) ofloxacin is white or little yellow crystalline powder; Odorless, bitter in the mouth; Meet light gradual change color.
(d) dexamethasone sodium phosphate is white or micro-yellow powder; Odorless, mildly bitter flavor; Have draw moist.Specification: 10ml: sulfamonomethoxine sodium 1.5g+ trimethoprim 0.3g+ ofloxacin 0.2g+ dexamethasone sodium phosphate 0.01g.
Composite sulfamonomethoxine sodium injection title and naming basis:
The compound recipe sterile water solution that this product is made into by sulfamonomethoxine sodium, trimethoprim, ofloxacin and dexamethasone sodium phosphate, trimethoprim can significantly improve the bacterial action extremely that presses down of sulfamonomethoxine sodium.Because this product is by the composite injection that forms of multiple material, and the principal agent composition is a sulfamonomethoxine sodium, according to the preparation naming rule with its called after:
Common name: composite sulfamonomethoxine sodium injection
Trade name: Jin Yian
English name: Compounnd Sulfamonomethoxine Sodium Injection
The Chinese phonetic alphabet: Fufang Huang ' an Jianjiayang Miding Na Zhusheye
Formula for a product foundation: " Hunan Province's veterinary drug quality standard ".
The beneficial effect that composite sulfamonomethoxine sodium injection of the present invention has: sulfamonomethoxine sodium, trimethoprim, ofloxacin, four kinds of medicines of dexamethasone sodium phosphate are organically combined, can be played effectively that medicine is collaborative, potentiation, long lasting effect; To improving curative effect of medication, enlarge antimicrobial spectrum, improving drug side effect far reaching significance is arranged.Particularly at present popular mixed sense disease, can a pin onset, the purpose that the 3-5 acupuncture is healed; Four folk prescription medicines are organically combined, save packaging material, reduce product cost, improved the added value of producing; Make the user by the injection of spininess injection a becoming pin simultaneously, easy to use; Be convenient to grasp dosage, hold best occasion for the treatment; Can reduce user's treatment cost, improve the aquaculture economic benefit.
In the popular mixed infection of domestic animal pig in China in 2006, produce this product as a trial through small lot, evident in efficacy, effectively cure rate reaches 95%, be subjected to the favorable comment at vast family on probation, having obtained the consistent of users affirms, the bacteriostatic test result, clinical test results and pilot-scale experiment all show, sulfamonomethoxine sodium and trimethoprim in this product, ofloxacin was with 15: 3: 2 proportionings, intramuscular or quiet notes, to the poultry Eperythrozoon, toxoplasma, mycoplasma, streptococcus, the reproductive and respiratory syndrome poison, antibacterials such as circular virus, infection that virus causes and mixed infection, and difficult miscellaneous diseases, innominate high fever, it is remarkable that coccidium infection and chicken live therapeutic effect such as coccidium syphilidis infection.
In JIUYUE, 2006, it is the disease of cardinal symptom that Hunan Province Youxian County breaks out with auricle, afterbody and limb end cyanosis in poultry breeding breeding farm, and through tentative diagnosis, doubting is eperythrozoonosis, we have carried out the clinical trial of treatment swine eperythrozoonosis bacterium for this reason, and its result of the test is as follows:
1. test material
1.1 test drug
Composite sulfamonomethoxine sodium injection of the present invention, product batch number: 20040208, date of manufacture: on February 8th, 2004, specification: 10ml: sulfamonomethoxine sodium 1.5g+ trimethoprim 0.3g+ ofloxacin 0.2g+ dexamethasone sodium phosphate 0.01g, usage and dosage: pig per kilogram of body weight 0.05～0.10ml.
Control drug: sulfamonomethoxine sodium and trimethoprim provide for zhuzhou, hunan province city legendary god of farming animal pharmaceutcal corporation, Ltd.Be made into 20% sulfamonomethoxine sodium and 4% trimethoprim injection with water for injection.
1.2 experimental animal
The DLY three way cross piglet of Hunan Province Youxian County poultry breeding breeding farm natural occurrence, 40～50 ages in days, body weight is 11.6～13.8kg, totally 60.
2 test methods
2.1 the diagnosis of swine eperythrozoonosis
2.1.1 clinical symptoms
Suffer from temperature of pig body and raise and reach 40 ℃～42 ℃, be and delay pattern of fever, anorexia, bradykinesia is reluctant activity.Visible subsequently nasal secretion increases, cough, and dyspnea, visual mucosa is pale, jaundice.The feces initial stage is stiff and have mucus and mucosa, and constipation and diarrhoea alternately take place.Auricle, afterbody and limb end skin cyanosis are kermesinus or aubergine.
2.1.2 pathological change
Suffer from pig and typical icteroanemia occurs, cut open the visible mucosa of inspection, palor for eperythrozoonosis characteristic pathological change after death, blood is thin, spleen enlargement, lymphadenectasis, ascites, hydrothorax, hydropericardium.Histopathologic examination has: cerebrovascular endothelial cell swelling has the serosity cellulose to ooze out, brain mantle hyperemia, hemorrhage, a large amount of leukocyte recruitments.Neurocyte nuclear swelling, necrosis, fragmentation.Bone marrow proliferation.Liver has iron content blood flavochrome deposition, the lobules of liver partial necrosis, and hepatocyte cloudy swelling, vacuolar degeneration have petechial hemorrhage and necrosis region, the central vein expansion, edema, hepatic sinusoid expansion, interlobular bile duct expansion, interstitial pneumonia, splenaemia, hemorrhage, the folliculus fibroplasia, folliculus disappears.
2.1.3 experiment is to checking
2.1.3.1 one of blood is got in the check of blood tabletting, adding normal saline puts on the microscope slide, lid is with coverslip, amplify 1000 times of observations with oily mirror after dripping cedar oil, under mirror, see barbed erythrocyte (being dentation) is arranged, adhere to some semicircles or circular attachment (have that the wolf tooth of title is bar-shaped, Fructus Ananadis comosi shape, lemon-like etc.) around the erythrocyte, erythrocyte also has slight vibration, and erythrocytic shrinkage, distortion etc.And in blood plasma, seeing the situation that the circular or unsetting object that moves about not of uniform size is arranged, we are diagnosed as eperythrozoonosis in view of the above.
2.1.3.2 three of every pig pushing blood sheets of blood push jack dyeing check, dry back is fixing, respectively dyes one with Ji's nurse Sa and auspicious Te Shi dye liquor, puts under the oily mirror and observes.Detect discoid, spherical, ring-type in erythrocyte surface or blood plasma, being slightly, the lilac red size is the eperythrozoon suis of 0.8～2.5 μ m.
2.1.3.3 animal inoculation test
Get each 2ml of blood of the blood of 3 pigs that die of illness and 1 healthy no Eperythrozoon easy infection pig, respectively add penicillin and streptomycin 1000 units, be inoculated in respectively 2 of the healthy rabbits (2～3 monthly age) of Eperythrozoon feminine gender respectively, observed for 2 weeks.The result: sick pig blood inoculation rabbit is after 4 days, rabbit performance spirit is depressed, by Mao Songluan, not active, after 7 days, blood examination, find that erythrocyte surface has polypide to adhere to, all with identical seen in the above-mentioned Sanguis sus domestica sheet, the erythrocyte infection rate is 60%～80% for its form, size and mobility, the visual mucosal pallor of rabbit, performance are obviously become thin after 10 days, and the erythrocyte infection rate is more than 80%; Behind the health pig blood inoculation rabbit, the contrast rabbit does not have clinical manifestation, and blood does not detect Eperythrozoon yet.
2.1.4 make a definite diagnosis
According to above diagnostic result, we can determine that this disease is an eperythrozoonosis.
2.2 experimental animal grouping
All test pig are divided into 6 groups, are respectively the high, medium and low dosage treatment group of composite sulfamonomethoxine sodium injection, 20% sulfamonomethoxine sodium injection contrast treatment group, 4% trimethoprim injection contrast treatment group, the not administration matched group of falling ill.Experiment pig grouping and disposition see Table 1.
2.3 experimental treatment
When morbidity the last about 10 days, fervescence, jaundice, anemia only appearred in pig, and spirit is depressed, appetite descends or during useless symptom such as exhausted, press table 1 and respectively each is organized the pig administration.Measure rectal temperature and clinical symptom before each medication.Be 5 days the course of treatment, the observation period is after the administration for the first time 15 days, and the body condition before and after every pig tested is observed.
Grouping of table 1 experiment pig and disposition
| Medicine | Pig's head number (head) | Route of administration | Dosage (ml * kg -1) |
| Composite sulfamonomethoxine sodium injection low dosage | 10 | Intramuscular injection | 0.045 |
| Dosage in the composite sulfamonomethoxine sodium injection | 10 | Intramuscular injection | 0.09 |
| Composite sulfamonomethoxine sodium injection high dose | 10 | Intramuscular injection | 0.18 |
| 20% sulfamonomethoxine sodium injection | 10 | Intramuscular injection | 0.09 |
| 4% trimethoprim injection | 10 | Intramuscular injection | 0.09 |
| Matched group | 10 | - | - |
2.4 therapeutic evaluation index
2.4.1 mortality rate
At duration of test, the classical symptom and the death of eperythrozoonosis appears in sick pig, and necropsy has the typical characteristic sexually transmitted disease (STD) to become, the blood tabletting positive, and blood push jack Ji nurse Sa and the check of Rui Te Albert'stain Albert have Eperythrozoon to exist.Calculate mortality rate according to the death toll in every treated animal.
2.4.2 cure rate
At duration of test, body temperature, spirit, appetite are all recovered normally after the pig medication, clinical symptoms such as fervescence, jaundice, anemia no longer occur, calculate cure rate according to these pigs quantity only.
2.4.3 effective percentage
Body temperature reduces or recovers normal after pig of curing and the administration, and appetite increases, but the pig of symptoms such as jaundice, anemia occurs, all is judged to be effectively.Calculate effective percentage in view of the above.
2.4.4 data analysis and processing
Use the biological statistical method deal with data, wherein mortality rate, effective percentage and cure rate are all used X 2 test.
3 results
Not administration contrast pig fervescence all occurs and reaches 40 ℃～42 ℃ 3.1 the morbidity matched group is fallen ill, and spirit is depressed, inappetence, anemia, nasal secretion increases, cough, dyspnea, visual mucosa, palor, blood is thin, the spleen enlargement, lymphadenectasis, ascites, hydrothorax, hydropericardium.
3.2 experimental treatment
In 15 days, each mortality rate, cure rate, effective percentage of organizing pig sees Table 2 after the beginning administration.
Table 2 therapeutic outcome
| Medicine | Number of animals | A dead number | Mortality rate (%) | Cure a number | Cure rate (%) | Effective number | Effective percentage (%) |
| Composite sulfamonomethoxine sodium injection low dosage | 10 | 0 | 0.00 | 9 | 90.00 | 10 | 100.00 |
| Dosage in the composite sulfamonomethoxine sodium injection | 10 | 0 | 0.00 | 9 | 90.00 | 10 | 100.00 |
| Composite sulfamonomethoxine sodium injection high dose | 10 | 0 | 0.00 | 7 | 70.00 | 9 | 90.00 |
| 20% sulfamonomethoxine sodium injection | 10 | 1 | 10.00 | 4 | 40.00 | 6 | 60.00 |
| 4% trimethoprim injection | 10 | 1 | 10.00 | 3 | 30.00 | 4 | 40.00 |
| Matched group | 10 | 6 | 60.00 | -- | -- | -- | -- |
3.3 respectively organize mortality rate
The mortality rate of the high, medium and low dosage group of statistical analysis composite sulfamonomethoxine sodium injection and 20% sulfamonomethoxine sodium injection and 4% trimethoprim injection matched group, significant difference (P＜0.05); And 20% sulfamonomethoxine sodium injection medicine matched group is compared difference not remarkable (P＞0.05) with 4% trimethoprim injection matched group.Illustrate that the mortality rate of each dosage group of composite sulfamonomethoxine sodium injection is significantly less than the mortality rate of its folk prescription medicine matched group.
3.4 cure rate, effective percentage
The cure rate of the high, medium and low dosage group of statistical analysis composite sulfamonomethoxine sodium injection is compared with 4% trimethoprim injection matched group with 20% sulfamonomethoxine sodium injection with effective percentage, difference is (P＜0.01) extremely significantly, and promptly the cure rate of the high, medium and low dosage group of composite sulfamonomethoxine sodium injection and effective percentage are all high in its folk prescription medicine 20% sulfamonomethoxine sodium injection and 4% trimethoprim injection matched group; Composite sulfamonomethoxine sodium injection height, in, the effective percentage and the cure rate of dosage group compare mutually, difference is remarkable (P＞0.05) not, and composite sulfamonomethoxine sodium injection height, in, the cure rate of dosage group compares significant difference (P＜0.05) with composite sulfamonomethoxine sodium injection low dose group with effective percentage.Illustrate that respond well, if be lower than normal using dosage dispensing, though show sx in various degree, cure rate reduces if press Sulfamonomethoxine sodium injection normal dose or the use of a little higher than normal dose between compound recipe amine.
4 conclusions
Result of the test explanation composite sulfamonomethoxine sodium injection obviously is better than its single preparations of ephedrine to the therapeutical effect of eperythrozoon suis, and the height of its compound recipe, middle dosage group are compared difference not remarkable (P＞0.05).Its height, middle dosage group are compared, and significant difference (P＜0.05) uses the cure rate to eperythrozoon suis can reach more than 90% its cure rate height, determined curative effect by normal dose.
Below in conjunction with the specific embodiment the present invention is done detailed explanation:
Sulfamonomethoxine sodium 150g, trimethoprim 30g, ofloxacin 20g, dexamethasone sodium phosphate 1g, propylene glycol 600ml, ethanolamine is an amount of by prescription, benzyl alcohol 40ml, disodiumedetate 100mg, anhydrous sodium sulfite 2g, active carbon 3g, water for injection are an amount of, and substep is operated as follows;
The first step, get the propylene glycol of amount of preparation, in pill tank, be heated to 70～80 ℃, add the trimethoprim of amount of preparation, stir molten, standby;
Second step, get the water for injection of amount of preparation 20%, in pill tank, be heated to 40～50 ℃, add disodiumedetate, anhydrous sodium sulfite stirring and dissolving successively, add the total amount ethanolamine of (4%) approximately again, the adding ofloxacin fully stirs and makes its dissolving after stirring evenly, adding sulfamonomethoxine sodium again stirs molten, standby;
The 3rd step, to get water for injection an amount of, in preparation tank, adds dexamethasone sodium phosphate and stir molten, standby;
The 4th step, the reserve liquid that the first step is made under agitation add in the reserve liquid that second step made, add again in the 3rd reserve liquid that make of step and stir, regulate pH value to 10.0～11.5 with ethanolamine, the benzyl alcohol that adds amount of preparation stirs evenly, and adds active carbon in 70～80 ℃ of absorption 15 minutes, adds to the full amount of water for injection, stir evenly, coarse filtration, fine straining, promptly get the composite sulfamonomethoxine sodium injection, detect qualified after, packing;
The 5th step, again in 100 ℃ of flowing steam sterilizations 30 minutes, lamp inspection, the seal bag, product inspection is qualified, promptly gets the composite sulfamonomethoxine sodium injection.
Claims (2)
1. a composite sulfamonomethoxine sodium injection is characterized in that, the prescription of described composite sulfamonomethoxine sodium injection is:
Sulfamonomethoxine sodium 150g
Trimethoprim 30g
Ofloxacin 20g
Dexamethasone sodium phosphate 1g
Propylene glycol 600ml
Ethanolamine is an amount of
Benzyl alcohol 40ml
Disodiumedetate 100mg
Anhydrous sodium sulfite 2g
Active carbon 3g
Water for injection adds to 1000ml.
2. the preparation method of a composite sulfamonomethoxine sodium injection, it is characterized in that, sulfamonomethoxine sodium 150g, trimethoprim 30g, ofloxacin 20g, dexamethasone sodium phosphate 1g, propylene glycol 600ml, ethanolamine is an amount of, benzyl alcohol 40ml, disodiumedetate 100mg, anhydrous sodium sulfite 2g, active carbon 3g, water for injection are an amount of, operate as follows step by step:
The first step, get the propylene glycol of amount of preparation, in pill tank, be heated to 70～80 ℃, add the trimethoprim of amount of preparation, stir molten, standby;
Second goes on foot, gets the water for injection of amount of preparation 20%, in pill tank, be heated to 40～50 ℃, add disodiumedetate, anhydrous sodium sulfite stirring and dissolving successively, the ethanolamine that adds total amount 4%, the adding ofloxacin fully stirs and makes its dissolving after stirring evenly, and adds sulfamonomethoxine sodium again and stirs molten, standby;
The 3rd step, to get water for injection an amount of, in preparation tank, adds dexamethasone sodium phosphate and stir molten, standby;
The 4th step, the reserve liquid that the first step is made under agitation add in the reserve liquid that second step made, add again in the 3rd reserve liquid that make of step and stir, regulate pH value to 10.0～11.5 with ethanolamine, the benzyl alcohol that adds amount of preparation stirs evenly, and adds active carbon in 70～80 ℃ of absorption 15 minutes, adds the injection water to 1000ml, stir evenly, coarse filtration, fine straining, promptly get the composite sulfamonomethoxine sodium injection, detect qualified after, packing;
The 5th step, again in 100 ℃ of flowing steam sterilizations 30 minutes, lamp inspection, seal bag, the qualified composite sulfamonomethoxine sodium injection that promptly gets of product inspection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710034835A CN100589807C (en) | 2007-04-28 | 2007-04-28 | Compound and its processing technology for compound sulfamonomethoxine sodium injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710034835A CN100589807C (en) | 2007-04-28 | 2007-04-28 | Compound and its processing technology for compound sulfamonomethoxine sodium injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101053568A CN101053568A (en) | 2007-10-17 |
| CN100589807C true CN100589807C (en) | 2010-02-17 |
Family
ID=38793735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710034835A Expired - Fee Related CN100589807C (en) | 2007-04-28 | 2007-04-28 | Compound and its processing technology for compound sulfamonomethoxine sodium injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100589807C (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA92423C2 (en) * | 2009-07-24 | 2010-10-25 | Анатолій Альбертович Кузьмін | Antibacterial composition |
| CN101829124B (en) * | 2010-05-19 | 2012-04-18 | 陈建波 | Veterinary compound sulfadiazine sodium injection and preparation method thereof |
| CN102188436B (en) * | 2011-03-28 | 2012-07-11 | 郑州百瑞动物药业有限公司 | Injection for treating porcine mixed infection |
| CN102697788B (en) * | 2012-06-27 | 2013-09-04 | 苏州科牧动物药品有限公司 | Compound lactic acid levofloxacin oral liquid and preparation process thereof |
| CN102743395B (en) * | 2012-07-31 | 2013-04-03 | 山东中牧兽药有限公司 | Compound ofloxacin injecta and preparation method thereof |
| CN103006674B (en) * | 2012-12-14 | 2015-12-02 | 江苏恒丰强生物技术有限公司 | A kind of compound sulfamonomethoxine sodium solution and preparation method thereof |
| CN104274472A (en) * | 2014-09-12 | 2015-01-14 | 安徽天安动物药业有限公司 | Compound sulfamonomethoxine sodium injection and preparation method thereof |
| CN108524467A (en) * | 2018-07-02 | 2018-09-14 | 合肥中龙神力动物药业有限公司 | A kind of composite sulfamonomethoxine sodium microcapsule formulation and preparation method thereof |
| CN109602701A (en) * | 2019-02-22 | 2019-04-12 | 湖北九州通中加医药有限公司 | A kind of dexamethasone sodium phosphate injection and preparation method thereof |
-
2007
- 2007-04-28 CN CN200710034835A patent/CN100589807C/en not_active Expired - Fee Related
Non-Patent Citations (8)
| Title |
|---|
| 养猪用药指南. 吴树兰等，第63-66页,第100-101页，中国农业出版社. 2001 |
| 养猪用药指南. 吴树兰等，第63-66页,第100-101页，中国农业出版社. 2001 * |
| 兽用10%复方新诺明注射液的配制. 郝勃等.兽药与饲料添加剂，第2期. 1999 |
| 兽用10%复方新诺明注射液的配制. 郝勃等.兽药与饲料添加剂，第2期. 1999 * |
| 复方磺胺间甲氧嘧啶注射液对猪无名高热的临床疗效试验. 张纯林等.中国动物保健，第9期. 2005 |
| 复方磺胺间甲氧嘧啶注射液对猪无名高热的临床疗效试验. 张纯林等.中国动物保健，第9期. 2005 * |
| 猪链球菌病与附红细胞体病及混合感染的诊治. 刘洪贵等.农村养殖技术，第7期. 2005 |
| 猪链球菌病与附红细胞体病及混合感染的诊治. 刘洪贵等.农村养殖技术，第7期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101053568A (en) | 2007-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100589807C (en) | Compound and its processing technology for compound sulfamonomethoxine sodium injection | |
| CN104719671A (en) | Compound essential oil for preventing diarrhea of piglets as well as preparation method and application of compound essential oil | |
| CN107456509B (en) | A kind of external application biological agent and preparation method for vagina prevention, health care and treatment gynaecology genital inflammation | |
| CN101836691A (en) | Chinese medicinal herb feed additive | |
| CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
| CN109453278A (en) | A kind of external application bacteriostatic Chinese medicinal particle and preparation method thereof | |
| EP2985029A1 (en) | External-use medicament for cleaning and care of the ovaries, vagina and vulva | |
| CN1686185A (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
| CN101797269A (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN101468057A (en) | Compound Chinese medicine preparation for treating yellow-white dysentery of piglet | |
| CN103356767A (en) | Medicinal composition for treating bacterial diarrhea of livestock as well as preparation method and application thereof | |
| CN1903254A (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
| CN101574355B (en) | Compound antibacterial injection for livestock and preparation method thereof | |
| CN1739682A (en) | Nudiflorous beautyberry soft capsule for body cavity and its prepn | |
| CN1191066C (en) | Externally-used disinfector | |
| CN106309394A (en) | Metronidazole oral sticking tablets and preparation method thereof | |
| CN102836152B (en) | Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis | |
| CN101972451B (en) | Compound infusion preparation of Chinese herbal medicines and western medicines for treating cow hysteritis and preparation method thereof | |
| CN101982188B (en) | Application of Tangut dragonhead in preparation of drugs for treating livestock and poultry viral infectious diseases | |
| CN1970068A (en) | Effervescence tablet for treating colpitis, preparation method and use thereof | |
| CN108785383A (en) | A kind of antibacterial gynecology externally used pharmaceutical combination and the preparation method and application thereof | |
| CN105012201B (en) | The oral care product with anti-helicobacter pylori of the alcohol extract containing Chinese hawthorn seed | |
| CN104784657B (en) | A kind of application of herbal medicine compound preparation in treating chicken colibacillosis | |
| CN102670811B (en) | External medicament for treating bacterial vaginosis and colpitis mycotica | |
| CN102631360A (en) | Application of oleanane glycoside to preparation of drugs for treating and/or preventing schistosomiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100217 Termination date: 20130428 |